Q2 2024 |
9 |
$859M |
+$616M |
-$493M |
+$123M |
CYTK, INSM, PCVX, GERN, KROS
|
13F-HR |
8/14/2024, 04:26 PM |
Q1 2024 |
12 |
$751M |
+$637M |
-$427M |
+$210M |
PCVX, NUVL, KROS, BHVN, ALPN
|
13F-HR |
5/15/2024, 04:33 PM |
Q4 2023 |
8 |
$509M |
+$509M |
-$284M |
+$225M |
AMAM, TGTX, MLTX, CYTK, KROS
|
13F-HR |
2/14/2024, 04:59 PM |
Q3 2023 |
3 |
$284M |
+$69.8M |
-$342M |
-$273M |
AMAM, IMVT, ARGX
|
13F-HR |
11/14/2023, 04:40 PM |
Q2 2023 |
3 |
$612M |
+$88.6M |
-$35.1M |
+$53.5M |
AMAM, TGTX, ARGX
|
13F-HR |
8/14/2023, 11:13 AM |
Q1 2023 |
4 |
$366M |
+$190M |
-$31.7M |
+$159M |
TGTX, ARGX, AMAM, KROS
|
13F-HR |
5/15/2023, 05:12 PM |
Q4 2022 |
4 |
$161M |
+$161M |
-$66.4M |
+$94.2M |
ARGX, KROS, AMAM, RXDX
|
13F-HR |
2/14/2023, 02:18 PM |
Q3 2022 |
2 |
$66.4M |
+$66.4M |
-$188M |
-$122M |
VTYX, KRTX
|
13F-HR |
11/14/2022, 04:51 PM |
Q2 2022 |
1 |
$188M |
+$78.5M |
$0 |
+$78.5M |
AZN
|
13F-HR |
8/15/2022, 04:26 PM |
Q1 2022 |
1 |
$110M |
+$76.3M |
-$625M |
-$548M |
AZN
|
13F-HR |
5/16/2022, 04:27 PM |
Q4 2021 |
13 |
$655M |
+$521M |
-$400M |
+$121M |
PFE, NTLA, AZN, INBX, BNTX
|
13F-HR |
2/14/2022, 04:20 PM |
Q3 2021 |
12 |
$543M |
+$96M |
-$189M |
-$93.1M |
XLRN, NTLA, BNTX, FATE, INBX
|
13F-HR |
11/15/2021, 04:27 PM |
Q2 2021 |
12 |
$620M |
+$372M |
-$252M |
+$120M |
NTLA, XLRN, FATE, BBIO, BEAM
|
13F-HR |
8/16/2021, 04:27 PM |
Q1 2021 |
12 |
$511M |
+$249M |
-$82.8M |
+$166M |
XLRN, BBIO, FATE, RLAY, ARVN
|
13F-HR |
5/17/2021, 04:50 PM |
Q4 2020 |
12 |
$358M |
$0 |
$0 |
|
XLRN, FATE, MRTX, BBIO, SRPT
|
13F-HR |
2/16/2021, 05:06 PM |